InvestSMART

Imugene Limited (ASX: IMU) - Announcements

- Current share price for IMU : $0.068

ASX company news and announcements for Imugene Limited (IMU) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Imugene Limited (IMU) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Imugene Limited (IMU), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Imugene Limited (IMU)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$35 Notice Under Section 708A 3 Nov 2022 5:03PM $0.190 $0.068 fallen by 64.21%
$35 Application for quotation of securities - IMU 3 Nov 2022 4:57PM $0.190 $0.068 fallen by 64.21%
$35 First patient dosed in VAXINIA intratumoral cohort 2 31 Oct 2022 8:45AM $0.165 $0.068 fallen by 58.79%
$35 Quarterly Activities/Appendix 4C Cash Flow Report 28 Oct 2022 4:48PM $0.165 $0.068 fallen by 58.79%
$35 Application for quotation of securities - IMU 27 Oct 2022 5:39PM $0.190 $0.068 fallen by 64.21%
$35 Application for quotation of securities - IMU 21 Oct 2022 4:30PM $0.170 $0.068 fallen by 60%
$35 Letter to IMUOC Optionholders 19 Oct 2022 6:25PM n/a $0.068 n/a
$35 Release of Shares from Escrow 19 Oct 2022 5:25PM n/a $0.068 n/a
$35 ABL and Imugene partner to advance VAXINIA manufacturing 18 Oct 2022 6:02PM $0.180 $0.068 fallen by 62.22%
$35 Notice of Annual General Meeting/Proxy Form 14 Oct 2022 6:32PM $0.170 $0.068 fallen by 60%
$35 Application for quotation of securities - IMU 13 Oct 2022 5:28PM $0.170 $0.068 fallen by 60%
$35 HERIZON study results to be featured at ESMO Asia Congress 7 Oct 2022 9:47AM $0.190 $0.068 fallen by 64.21%
$35 onCARlytics to be showcased in three abstracts at SITC 6 Oct 2022 9:28AM $0.190 $0.068 fallen by 64.21%
$35 Imugene appoints Paul Wright as Vice President CMC 4 Oct 2022 8:34AM $0.185 $0.068 fallen by 63.24%
$35 Imugene appoints Dr Giovanni Selvaggi as CMO 4 Oct 2022 8:31AM $0.185 $0.068 fallen by 63.24%
$35 ALA iNKT therapy and IMU onCARlytics - correction 27 Sep 2022 9:01AM $0.180 $0.068 fallen by 62.22%
$35 ALA: Investor Presentation Imugene Arovella Therapies 26 Sep 2022 10:33AM $0.180 $0.068 fallen by 62.22%
$35 Preclinical trial of ALA iNKT therapy and IMU onCARlytics 26 Sep 2022 9:55AM $0.190 $0.068 fallen by 64.21%
$35 First patient IV dosed in VAXINIA Phase 1 clinical trial 21 Sep 2022 9:29AM $0.230 $0.068 fallen by 70.43%
$35 Notification regarding unquoted securities - IMU 20 Sep 2022 3:54PM $0.230 $0.068 fallen by 70.43%
$35 Notice Under Section 708A 19 Sep 2022 5:18PM $0.220 $0.068 fallen by 69.09%
$35 Application for quotation of securities - IMU 19 Sep 2022 5:12PM $0.220 $0.068 fallen by 69.09%
$35 OGTR grants VAXINIA DIR licence allowing trial expansion 19 Sep 2022 9:46AM $0.220 $0.068 fallen by 69.09%
$35 Prospectus for the issue of institutional placement options 16 Sep 2022 12:21PM $0.218 $0.068 fallen by 68.74%
$35 Proposed issue of securities - IMU 13 Sep 2022 8:54AM $0.225 $0.068 fallen by 69.78%

401 - 425 of 1199 results

Page 17 of 48

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.